Promising research results from a Multi-Frequency Vibrometry study will be presented at the European Association for the Study of Diabetes in Berlin
The senior specialist at Skåne University Hospital, Dr. Eero Lindholm, will present study results showing that it may be possible to reverse nerve damage in feet caused by diabetes by improved metabolic control. VibroSense Dynamics participates as an exhibitor at EASD in Hall 4 at booth 4J05.
Dr. Lindholm's poster presentation shows very promising results which indicate that impairment of the nerve function of the feet caused by diabetes may be reversible by means of improved metabolic control.
Improved metabolic control means in this respect that patients that lowers their long-term blood sugar (HbA1c) also improve the tactile senisitivity in their feet.
This is the second time that Dr. Eero Lindholm presents research findings at EASD. Dr. Lindholm has previously presented results that showed that Multi-Frequency Vibrometry disclose that there is a significant correlation between foot ulcers and impaired sensitivity in feet at low frequencies, 4-16 Hz.
VibroSense Dynamics participates as an exhibitor at EASD and will show the new CE-marked VibroSense Meter® II instrument in hall 4, stand 4J05.
EASD is one of the world's most important conferences for researchers in diabetes. EASD has more than 5,000 members from more than 100 countries. This year's conference takes place on 1-5 October and more than 15,000 delegates from more than 130 countries participate.
We are now taking an important step forward as we are able to show the benefits with our VibroSense Meter device and Multi Frequency Vibrometry with convincing research results. For the first time ever, it has been shown that it may be possible to reverse nerve damage in the feet causing diabetes, which in that case is very good news for all diabetic patients, says Toni Speidel, CEO VibroSense Dynamics AB.
Toni Speidel, CEO VibroSense Dynamics AB,
Tel: +46 40 650 14 12
About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (public) develops and markets efficient systems to support early detection and diagnosis of sensory neuropathy, i.e. disease of large nerve fibres and nerve trunks in e.g. legs and arms. The Company, founded in 2005, has been listed on Spotlight stock market since May 2015.